ESPERION Q1 2021 CONFERENCE CALL

May 4th, 2021

ESPERION The Lipid Management Company

SAFE HARBOR

FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the global clinical development and commercialization plans for bempedoic acid tablet and the bempedoic acid / ezetimibe fixed dose combination tablet, including ESPERION's timing, designs, plans for announcement of results regarding its CLEAR Outcomes study and other ongoing clinical studies for bempedoic acid tablet and the bempedoic acid / ezetimibe combination fixed dose tablet, timing for the review and approval of expanded indications for their effect on cardiovascular events, ESPERION's expectations for the market for medicines to lower LDL-C, including the prospects for success of the commercial launch and market adoption of bempedoic acid tablet and the bempedoic acid / ezetimibe fixed dose combination tablet in the United States and European Union, the development of ESPERION's in-licensed pre-clinical oral PCSK9 inhibitor program, and ESPERION's financial outlook, including expectations for future revenues from its product sales, partnership collaborations and other sources. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause ESPERION's actual results to differ significantly from those projected, including, without limitation, delays or failures in ESPERION's clinical development and the commercialization plans of both ESPERION and Daiichi Sankyo group, failure to obtain the approval of bempedoic acid or the bempedoic acid / ezetimibe combination tablet or expanded indications in countries outside of the U.S., or approval of expanded indications, that existing cash resources may be used more quickly than anticipated, that Otsuka and Daiichi Sankyo are able to successfully commercialize its products, the impact of COVID-19 on our business, clinical activities, supply chain, commercial development and launch plans, and the risks detailed in ESPERION's filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and ESPERION disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

BUSINESS HIGHLIGHTS

Tim M. Mayleben, President & CEO

ESPERION The Lipid Management Company

ESPERION Q1 2021 HIGHLIGHTS

AND RECENT BUSINESS UPDATES

- Progressed on implementing new refined commercial strategy with majority of initiatives in place
- Demonstrated sequential prescription growth of 46% from Q4 2020 with over 35,000 cumulative patients on therapy at Q1 2021 end
- Secured major payor formulary coverage for NEXLETOL and NEXLIZET, adding 8.5 million Medicare Part D lives
- Continued to advance CLEAR Outcomes study uninterrupted and initiated Real-World evidence study
- Otsuka initiated Phase II study in Japan
- Completed Daiichi Sankyo relationship expansion in select countries across ASCA region
- Strengthened balance sheet with additional $80 million in non-dilutive funds from expanded Daiichi Sankyo relationship and Oberland Capital third tranche

OPERATIONS OVERVIEW

Sheldon Koenig, COO

ESPERION® The Lipid Management Company

ADVANCING OPERATIONAL EXCELLENCE INITIATIVES

DRIVE AWARENESS

- Leverage Medical Science Liaisons
- Establish Scientific Platform

EXPAND MEDICAL EDUCATION

- Introduced Enhance Product Positioning
- Initiated Real World Evidence Study
- Promote Health Economics Benefits

PULL THROUGH MANAGED CARE

- Secured Formulary Coverage of Major Provider

SCRIPTS GREW 46% SEQUENTIALLY FROM Q4 2020

DESPITE COVID-19 SURGE AND TYPICAL INDUSTRY Q1 SEASONALITY

QUARTERLY FRANCHISE RPE TREND



WEEKLY FRANCHISE RPE TREND SINCE LAUNCH



*Based on Symphony data

RPE = Retail Prescription Equivalence; derived by normalizing the extended units Rx (no. of tablets) to determine the 30-day supply equivalent

ESPERION

MARKET TRENDS INDICATE LAUNCH TAILWINDS

STATIN NBRX AND CARDIOLOGY OFFICE CLAIMS NEAR NORMAL

CARDIOLOGY VISIT CLAIMS VS PRE-COVID BASELINE



Source: IQVIA COVID-19 Market Tracking Report, Customized View, April 2021

STATIN NEW-TO-BRAND PRESCRIPTIONS



Source: Symphony

ESPERION

UNDERLYING DEMAND CONTINUES TO GROW

NUMBER OF TOTAL PATIENTS GREW 60% IN Q1 2021

>35,000 CUMULATIVE U.S. PATIENTS AS OF Q1 2021 END



UNIQUE WRITERS CONTINUE TO INCREASE



FINANCIAL UPDATE

Rick Bartram, CFO

ESPERION The Lipid Management Company

CAPITAL POSITION & KEY FINANCIALS

Capitalized on Two Non-Equity-Dilutive Funding Sources

Cash, cash equivalents, and investment securities available-for-sale as of **March 31, 2021**	**$218M**
Oberland Capital third tranche	**$50M**
Expanded Daiichi Sankyo agreement upfront cash payment	**$30M**
Q1 2021 Pro-forma Cash Balance[2]	**$298M**
Future Ex-US collaboration milestones	**>$1.2B**

Key Financial Data	
FY 2021 Revenue	No Guidance Before 2022
FY 2021 R&D Guidance	$120 - $130 Million
FY 2021 SG&A Guidance	$200 - $210 Million
FY 2021 Op Ex Guidance[1]	$320 - $340 Million
Q1 2021 Common Shares Outstanding[3]	26.2 Million

[1] Includes $30M of non-cash stock based compensation expense
[2] Cash, cash equivalents and investment securities available for sale as of quarter end, inclusive of the $30M Daiichi upfront payment and $50M Oberland Capital third funding tranche
[3] Accounts for $50M prepaid forward feature

ESPERION

THANK YOU

ESPERION The Lipid Management Company